AbbVie to Acquire Pharmacyclics: What it Means For Mutual Fund Investors (ABBV, PCYC)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Abbvie company logo

News

AbbVie to Acquire Pharmacyclics: What it Means For Mutual Fund Investors (ABBV, PCYC)

Shauna O'Brien Mar 05, 2015



Inside the Deal


This is the first deal that the company has made since its terminated deal to acquire Ireland-based Shire.

Shares of ABBV dropped 2.5% on the news, while PCYC sales surged over 10%.


AbbVie’s Drug Pipeline


Despite the opportunity, shares of ABBV are down today, as many analysts see PCYC’s Imbruvica drug as unable to meet ambitious sales estimates.


Mutual Funds to Watch



The Bottom Line


If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book